| Code | CSB-RA006045MB4HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to Plonmarlimab, targeting CSF2 (colony-stimulating factor 2), also known as granulocyte-macrophage colony-stimulating factor (GM-CSF). CSF2 is a critical cytokine that regulates the proliferation, differentiation, and activation of granulocytes and macrophages, playing essential roles in both innate and adaptive immunity. This protein is implicated in various inflammatory and autoimmune conditions, including rheumatoid arthritis, inflammatory bowel disease, and acute respiratory distress syndrome. Dysregulated CSF2 signaling has also been associated with certain malignancies and contributes to the inflammatory tumor microenvironment.
Plonmarlimab represents a therapeutic antibody developed to neutralize CSF2 activity, initially investigated for treating conditions characterized by excessive myeloid cell activation and inflammation. This biosimilar antibody provides researchers with a valuable tool for investigating CSF2-mediated signaling pathways, exploring myeloid cell biology, and studying the role of GM-CSF in disease pathogenesis. It supports investigations into immune regulation, inflammatory responses, and potential therapeutic interventions targeting the CSF2 axis.
There are currently no reviews for this product.